US · ATLN
Atlantic International Corp.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Billerica, MA 01821
- Website
- seqll.com
Price · as of 2024-12-31
$1.40
Market cap 223.78M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.84 | +1,960% |
| Intrinsic Value(DCF) | $1.43 | +2.14% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $4.31 | |||
| 2019 | $0.00 | $2.56 | |||
| 2020 | $0.00 | $1.39 | |||
| 2021 | $45.20 | $19,711.76 | $89,047.10 | $0.00 | $0.00 |
| 2022 | $16.56 | $57.80 | $7,286.37 | $0.00 | $0.00 |
| 2023 | $3.20 | $11.21 | $594.07 | $0.00 | $0.29 |
| 2024 | $3.57 | $28.84 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Atlantic International Corp.'s (ATLN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.84
- Current price
- $1.40
- AI upside
- +1,960%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.43
+2.14% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATLN | Atlantic International Co… | $1.40 | 223.78M | +1,960% | +2% | — | — | -0.97 | -10.93 | 0.30 | -1.89 | -0.19 | -3.02 | 10.66% | -4.93% | -30.61% | 527.46% | -25.40% | -108.64% | -6.88 | -1.82 | 0.91 | 0.76 | -0.73 | 51333.00% | 1027.00% | -3383.00% | -4.61% | -0.06 | -7.05% | 0.00% | 0.00% | 45.10% | -9.77 | -35.22 | 0.48 | 1.97 |
| AVR | Anteris Technologies Glob… | $6.51 | 239.49M | +229% | -58% | — | +1,116% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| IMDX | Insight Molecular Diagnos… | $6.01 | 172.27M | +228% | -74% | — | — | -0.84 | -4.15 | 27.10 | -0.78 | -3.46 | -1.90 | 39.34% | -3245.14% | -3225.04% | -1480.67% | 3654.06% | -110.32% | -0.30 | -726.68 | 1.62 | 1.41 | 0.08 | 2430.00% | 2515.00% | -1007.00% | -41.64% | -2.85 | 1270.82% | 0.00% | 0.00% | 0.00% | -0.75 | -2.17 | 24.46 | -18.88 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| NKTX | Nkarta, Inc. | $2.70 | 191.78M | — | — | — | — | -1.15 | 0.31 | — | 0.52 | — | 0.31 | 0.00% | — | — | -31.94% | -76.69% | -24.72% | 0.20 | — | 14.45 | 14.14 | -0.44 | -3333.00% | — | -893.00% | -83.37% | -5.27 | -62.28% | 0.00% | 0.00% | 3.92% | 0.49 | 0.60 | — | -0.95 |
| PEPG | PepGen Inc. | $6.22 | 427.61M | — | — | — | — | -0.81 | 0.61 | — | 0.32 | — | 0.61 | 0.00% | — | — | -79.26% | -551.43% | -61.23% | 0.16 | — | 7.41 | 7.20 | 0.35 | -1364.00% | — | 1575.00% | -113.83% | -4.93 | -470.74% | 0.00% | 0.00% | 0.00% | 0.29 | 0.35 | — | -2.45 |
| PRE | Prenetics Global Limited | $16.91 | 237.65M | +204% | +11,114% | — | — | -4.22 | 1.27 | 2.41 | -4.86 | -30.15 | 1.71 | 52.98% | -40.46% | -63.13% | -30.55% | -32.70% | -25.27% | 0.01 | -155.12 | 3.01 | 2.33 | 0.89 | 1401.00% | 20172.00% | -2645.00% | -9.89% | -0.79 | -19.26% | 0.00% | 0.00% | 0.00% | -4.37 | -7.42 | 1.77 | 4.78 |
| SAVA | Cassava Sciences, Inc. | $2.28 | 110.14M | — | — | — | — | -5.35 | 0.89 | — | -0.01 | — | 0.89 | 0.00% | — | — | -17.19% | -845.41% | -15.75% | 0.00 | — | 11.62 | 11.02 | 0.91 | -7759.00% | — | 4196.00% | -89.90% | -9.95 | -699.49% | 0.00% | 0.00% | 5.71% | -0.01 | -0.01 | — | 0.99 |
| STIM | Neuronetics, Inc. | $1.34 | 91.77M | +1,696% | +34,643% | — | — | -3.68 | 5.81 | 2.15 | -6.51 | -11.71 | -15.27 | 72.32% | -46.15% | -58.36% | -141.29% | -54.52% | -34.06% | 2.98 | -4.74 | 1.86 | 1.41 | -1.84 | 3143.00% | 496.00% | -565.00% | -20.18% | -0.99 | -51.22% | 0.00% | 0.00% | 0.00% | -6.48 | -6.90 | 2.99 | -3.34 |
| SXTC | China SXT Pharmaceuticals… | $2.28 | 1.95M | +6,431% | +5,777% | — | +346% | -35.58 | 7.61 | 67.52 | -39.03 | -27.55 | 7.62 | 21.11% | -153.97% | -189.77% | -22.50% | -189.29% | -14.75% | 0.06 | -4.14 | 3.54 | 3.33 | 6.65 | 12913.00% | -973.00% | 2130.00% | -2.00% | -0.39 | -165.76% | 0.00% | 0.00% | 6.54% | -37.47 | -42.78 | 57.69 | 10.04 |
About Atlantic International Corp.
As of June 18, 2024, Atlantic International Corp. was acquired by Lyneer Investments, LLC, in a reverse merger transaction. Atlantic International Corp. operates as a life sciences instrumentation and research services company. It focuses on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies. The company was formerly known as SeqLL Inc. and changed its name to Atlantic International Corp. in June 2024. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
- CEO
- Jeffrey Jagid
- Employees
- 300
- Beta
- 1.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.43 ÷ $1.40) − 1 = +2.14% (DCF, example).